{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:15:01Z","timestamp":1783397701594,"version":"3.54.6"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005743","name":"Universit\u00e0 Cattolica del Sacro Cuore","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005743","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To investigate the 12-month effectiveness and safety of intravitreal faricimab (IVF) in patients with neovascular age-related macular degeneration (nAMD) resistant to previous anti-VEGF treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Prospective, monocentric study including consecutive patients with resistant\/refractory nAMD switched to IVF between July 2023 and November 2024. Primary endpoints were safety, best corrected visual acuity (BCVA), central subfield thickness (CST), and subfoveal choroidal thickness. Secondary endpoints included changes in optical coherence tomography (OCT) and OCT angiography biomarkers: fluid prevalence, pigment epithelial detachment (PED) height, and vascular densities. All patients received four monthly loading doses of faricimab, with subsequent treat-and-extend regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study included 30 eyes of 30 patients. Mean follow-up was 14.2\u2009\u00b1\u20091.9\u00a0months and no adverse events were reported. BCVA significantly improved from 0.77 to 0.62 LogMAR at the end of the study period (p\u2009=\u20090.009), with 67% of eyes showing stable vision. CST significantly decreased from baseline (-57\u00a0\u03bcm on average,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), along with PED height which showed its main decrease during the loading phase. Forty-seven percent of eyes achieved complete macular dryness at week 16, with significant reduction in terms of subretinal fluid (SRF) and intraretinal fluid (IRF) prevalence. At the end of the study, 90% of patients achieved treatment intervals of at least q8w, with 27% of eyes being on q12w. Finally, no changes in superficial\/deep vessel densities were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Faricimab demonstrated efficacy and safety in refractory\/resistant nAMD, with significant improvements in structural outcomes and stable\/improved visual acuity. Extended treatment intervals suggest a potential reduction in treatment burden.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10792-025-03717-w","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T05:11:15Z","timestamp":1755580275000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["One-year outcomes of faricimab for neovascular age related macular degeneration with OCT angiography: focus on resistant and refractory cases"],"prefix":"10.1007","volume":"45","author":[{"given":"Alessandra","family":"Scampoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2979-1638","authenticated-orcid":false,"given":"Matteo Mario","family":"Carl\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Grieco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Governatori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Catalani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislao","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomaso","family":"Caporossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"key":"3717_CR1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/jama.2023.26074","volume":"331","author":"M Fleckenstein","year":"2024","unstructured":"Fleckenstein M, Schmitz-Valckenberg S, Chakravarthy U (2024) Age-related macular degeneration: a review. JAMA 331:147\u2013157","journal-title":"JAMA"},{"key":"3717_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2019.100825","volume":"76","author":"MP Rozing","year":"2020","unstructured":"Rozing MP, Durhuus JA, Krogh Nielsen M, Subhi Y, Kirkwood TB, Westendorp RG, Sorensen TL (2020) Age-related macular degeneration: a two-level model hypothesis. Prog Retin Eye Res 76:100825","journal-title":"Prog Retin Eye Res"},{"key":"3717_CR3","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1007\/s00417-019-04456-2","volume":"257","author":"C Hara","year":"2019","unstructured":"Hara C, Wakabayashi T, Fukushima Y, Sayanagi K, Kawasaki R, Sato S, Sakaguchi H, Nishida K (2019) Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept. Graefes Arch Clin Exp Ophthalmol 257:2559\u20132569","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3717_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100906","volume":"82","author":"PS Mettu","year":"2021","unstructured":"Mettu PS, Allingham MJ, Cousins SW (2021) Incomplete response to anti-VEGF therapy in neovascular AMD: exploring disease mechanisms and therapeutic opportunities. Prog Retin Eye Res 82:100906","journal-title":"Prog Retin Eye Res"},{"key":"3717_CR5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1167\/iovs.64.5.28","volume":"64","author":"D Sharma","year":"2023","unstructured":"Sharma D, Zachary I, Jia H (2023) Mechanisms of acquired resistance to anti-VEGF therapy for neovascular eye diseases. Invest Ophthalmol Vis Sci 64:28","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3717_CR6","doi-asserted-by":"crossref","unstructured":"Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, Heier JS, Holz FG, Iida T, Ives JA, Lim JI, Lin H, Michels S, Quezada Ruiz C, Schmidt-Erfurth U, Silverman D, Singh R, Swaminathan B, Willis JR, Tadayoni R, Tenaya, Investigators L. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2. Ophthalmology 2024; 131: 914\u201326.","DOI":"10.1016\/j.ophtha.2024.02.014"},{"key":"3717_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40942-024-00525-9","volume":"10","author":"FM Penha","year":"2024","unstructured":"Penha FM, Masud M, Khanani ZA, Thomas M, Fong RD, Smith K, Chand A, Khan M, Gahn G, Melo GB, Khanani AM (2024) Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME. Int J Retina Vitreous 10:5","journal-title":"Int J Retina Vitreous"},{"key":"3717_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1159\/000529817","volume":"246","author":"A Scupola","year":"2023","unstructured":"Scupola A, Carla MM, Boselli F, Giannuzzi F, De Filippis A, Fossataro C, Minnella AM, D\u2019Amico G, Coppola G, Savastano MC, Sammarco MG, Rizzo S (2023) Brolucizumab for wet age-related macular degeneration: one-year real-world experience from a tertiary center. Ophthalmologica 246:58\u201367","journal-title":"Ophthalmologica"},{"key":"3717_CR9","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/aos.15783","volume":"102","author":"E Vinge","year":"2024","unstructured":"Vinge E, Bro T (2024) Treatment burden on patients receiving intravitreal anti-VEGF for wet age-related macular degeneration. Acta Ophthalmol 102:478\u2013482","journal-title":"Acta Ophthalmol"},{"key":"3717_CR10","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1007\/s40123-024-00980-5","volume":"13","author":"E Giancipoli","year":"2024","unstructured":"Giancipoli E, Guglielmi A, Bux AV, Clima GME, Pignatelli F, Boscia F, Viggiano P, Boscia G, Fortunato F, Besozzi G, Niro A, Dore S, Iaculli C (2024) Real-world outcomes of a loading phase with intravitreal faricimab in neovascular age-related macular degeneration (n-AMD) and diabetic macular edema (DME). Ophthalmol Ther 13:2163\u20132184","journal-title":"Ophthalmol Ther"},{"key":"3717_CR11","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40942-024-00586-w","volume":"10","author":"G Grimaldi","year":"2024","unstructured":"Grimaldi G, Cancian G, Paris A, Clerici M, Volpe G, Menghini M (2024) Intravitreal faricimab for treatment naive patients with neovascular age-related macular degeneration: a real-world prospective study. Int J Retina Vitreous 10:70","journal-title":"Int J Retina Vitreous"},{"key":"3717_CR12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s10384-023-01040-4","volume":"68","author":"H Matsumoto","year":"2024","unstructured":"Matsumoto H, Hoshino J, Nakamura K, Akiyama H (2024) One-year results of treat-and-extend regimen with intravitreal faricimab for treatment-naive neovascular age-related macular degeneration. Jpn J Ophthalmol 68:83\u201390","journal-title":"Jpn J Ophthalmol"},{"key":"3717_CR13","doi-asserted-by":"publisher","first-page":"11681","DOI":"10.1038\/s41598-024-62559-1","volume":"14","author":"R Mukai","year":"2024","unstructured":"Mukai R, Kataoka K, Tanaka K, Miyara Y, Maruko I, Nakayama M, Watanabe Y, Yamamoto A, Wakatsuki Y, Onoe H (2024) One-year outcomes and safety assessment of faricimab in treatment-na\u00efve patients with neovascular age-related macular degeneration in Japan. Sci Rep 14:11681","journal-title":"Sci Rep"},{"key":"3717_CR14","doi-asserted-by":"crossref","unstructured":"Schneider M, Subhi Y, Bjerager J, Hodzic-Hadzibegovic D, Klefter ON, Hajari JN. Short-term results with faricimab in neovascular age-related macular degeneration resistant to both ranibizumab and aflibercept. AJO International 2024; 1.","DOI":"10.1016\/j.ajoint.2024.100049"},{"key":"3717_CR15","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.2147\/OPTH.S482948","volume":"18","author":"BC Kunzmann","year":"2024","unstructured":"Kunzmann BC, Schweig AS, Bartz-Schmidt KU, Sobolewska B (2024) Real-world-data of treatment-naive and previously treated patients receiving up to 3 injections of faricimab in neovascular age-related macular degeneration. Clin Ophthalmol 18:4029\u20134039","journal-title":"Clin Ophthalmol"},{"key":"3717_CR16","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1038\/s41433-024-03364-y","volume":"38","author":"GA Borchert","year":"2024","unstructured":"Borchert GA, Kiire CA, Stone NM, Akil H, Gkika T, Fischer MD, Xue K, Cehajic-Kapetanovic J, MacLaren RE, Charbel Issa P, Downes SM, De Silva SR (2024) Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema. Eye (Lond) 38:3569\u20133577","journal-title":"Eye (Lond)"},{"key":"3717_CR17","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.2147\/OPTH.S424315","volume":"17","author":"RB Rush","year":"2023","unstructured":"Rush RB (2023) One-year outcomes of faricimab treatment for aflibercept-resistant neovascular age-related macular degeneration. Clin Ophthalmol 17:2201\u20132208","journal-title":"Clin Ophthalmol"},{"key":"3717_CR18","doi-asserted-by":"publisher","first-page":"21128","DOI":"10.1038\/s41598-023-48190-6","volume":"13","author":"R Tamiya","year":"2023","unstructured":"Tamiya R, Hata M, Tanaka A, Tsuchikawa M, Ueda-Arakawa N, Tamura H, Miyata M, Takahashi A, Kido A, Muraoka Y, Miyake M, Ooto S, Tsujikawa A (2023) Therapeutic effects of faricimab on aflibercept-refractory age-related macular degeneration. Sci Rep 13:21128","journal-title":"Sci Rep"},{"key":"3717_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/life14020193","author":"B Ng","year":"2024","unstructured":"Ng B, Kolli H, Ajith Kumar N, Azzopardi M, Logeswaran A, Buensalido J, Mushtaq B, Chavan R, Chong YJ (2024) Real-world data on faricimab switching in treatment-refractory neovascular age-related macular degeneration. Life (Basel). https:\/\/doi.org\/10.3390\/life14020193","journal-title":"Life (Basel)"},{"key":"3717_CR20","volume":"15","author":"AM Cheng","year":"2023","unstructured":"Cheng AM, Joshi S, Banoub RG, Saddemi J, Chalam KV (2023) Faricimab effectively resolves intraretinal fluid and preserves vision in refractory, recalcitrant, and nonresponsive neovascular age-related macular degeneration. Cureus 15:e40100","journal-title":"Cureus"},{"key":"3717_CR21","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.oret.2023.11.015","volume":"8","author":"R Raimondi","year":"2024","unstructured":"Raimondi R, Falfeli T, Bogdanova-Bennet A, Varma D, Habib M, Kotagiri A, Steel DH, Grinton M (2024) Outcomes of treatment-resistant neovascular age-related macular degeneration switched from aflibercept to faricimab. Ophthalmol Retina 8:537\u2013544","journal-title":"Ophthalmol Retina"},{"key":"3717_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/life14040476","author":"A Machida","year":"2024","unstructured":"Machida A, Oishi A, Ikeda J, Kurihara J, Yoneda A, Tsuiki E, Hirata Y, Murakami R, Kitaoka T (2024) Factors associated with success of switching to faricimab for neovascular age-related macular degeneration refractory to intravitreal aflibercept. Life (Basel). https:\/\/doi.org\/10.3390\/life14040476","journal-title":"Life (Basel)"},{"key":"3717_CR23","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1177\/11206721211005706","volume":"32","author":"M Karampelas","year":"2022","unstructured":"Karampelas M, Syriga M, Petrou P, Georgalas I, Papaconstantinou D, Brouzas D (2022) Morphometric analysis of fibrovascular pigment epithelial detachments treated with ranibizumab and aflibercept. Eur J Ophthalmol 32:347\u2013355","journal-title":"Eur J Ophthalmol"},{"key":"3717_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2024.04.001","author":"MA Salehi","year":"2024","unstructured":"Salehi MA, Frounchi N, Zakavi SS, Mohammadi S, Harandi H, Shojaei S, Gouravani M, Arevalo JF (2024) Retinal and choroidal changes after anti-VEGF therapy in neovascular-AMD patients: a systematic review and meta-analysis of SD-OCT studies. Surv Ophthalmol. https:\/\/doi.org\/10.1016\/j.survophthal.2024.04.001","journal-title":"Surv Ophthalmol"},{"key":"3717_CR25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ajo.2019.11.031","volume":"212","author":"SC Lee","year":"2020","unstructured":"Lee SC, Tran S, Amin A, Morse LS, Moshiri A, Park SS, Yiu G (2020) Retinal vessel density in exudative and nonexudative age-related macular degeneration on optical coherence tomography angiography. Am J Ophthalmol 212:7\u201316","journal-title":"Am J Ophthalmol"},{"key":"3717_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1080052","volume":"9","author":"C Turksever","year":"2022","unstructured":"Turksever C, Hoffmann L, Hatz K (2022) Peripapillary and macular microvasculature in neovascular age-related macular degeneration in long-term and recently started anti-VEGF therapy versus healthy controls. Front Med Lausanne 9:1080052","journal-title":"Front Med Lausanne"},{"key":"3717_CR27","doi-asserted-by":"crossref","unstructured":"Carl\u00e0 MM, Scampoli, Grieco G, Governatori L, Catalani R, Rizzo S, Caporossi, T. Morphometric Changes In Macular Neovascularization Architecture After Faricimab Treatment In Neovascular Age-Related Macular Degeneration: Comparison Between Na\u00efve And Switched Eyes. Retina 2025; 7.","DOI":"10.1097\/IAE.0000000000004635"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03717-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-025-03717-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03717-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T18:04:57Z","timestamp":1766167497000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-025-03717-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3717"],"URL":"https:\/\/doi.org\/10.1007\/s10792-025-03717-w","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,19]]},"assertion":[{"value":"10 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Approved by Universit\u00e0 Cattolica del Sacro Cuore Ethical Committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval Statement"}},{"value":"Written informed consent was obtained from all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent Statement"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"342"}}